TRANSITION PRESENTS RESULTS FROM ALZHEIMER'S THERAPY STUDY
Transition Therapeutics gave a presentation demonstrating that AZD-103 neutralizes and rescues amyloid beta inhibition of synaptic transmission in an experimental model associated with learning and memory at the Keystone Symposia on Alzheimer's disease, held in Breckenridge, Colorado.
This standard assay of hippocampal long-term potentiation (LTP) has been extensively described in the literature, and is widely accepted as a measure of synaptic efficacy and plasticity in the brain. The cellular and molecular basis of LTP employs closely similar mechanisms to those necessary for learning and memory in humans. In these studies, AZD-103 was shown to be highly effective at neutralizing the short-term effects of amyloid beta oligomers on synaptic function in the hippocampal slices from mice. Based on these very encouraging findings, AZD-103 continues to demonstrate the efficacy and safety profile necessary to be considered as a leading drug candidate for the treatment of Alzheimer's patients.